Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03899155
Other study ID # CA209-8TT
Secondary ID 2018-004362-34
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 9, 2019
Est. completion date August 25, 2029

Study information

Verified date April 2024
Source Bristol-Myers Squibb
Contact BMS Study Connect Contact http://www.bmsstudyconnect.com/
Phone 855-907-3286
Email Clinical.Trials@bms.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.


Recruitment information / eligibility

Status Recruiting
Enrollment 1500
Est. completion date August 25, 2029
Est. primary completion date August 25, 2029
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Signed Written Informed Consent. - Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study. - On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study. - WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF. Exclusion Criteria: - Participant is not eligible for study treatment per the Parent Study eligibility criteria. - Participants not receiving clinical benefit as assessed by the Investigator. - Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant. - Other protocol-defined Inclusion/Exclusion Criteria apply

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Cabozantinib
Specified dose on specified days
Trametinib
Specified dose on specified days
Relatlimab
Specified dose on specified days
Nivolumab + Relatlimab
Specified dose on specified days
Capecitabine
Specified dose on specified days
Bevacizumab
Specified dose on specified days
Temozolomide
Specified dose on specified days
Rucaparib
Specified dose on specified days
Daratumumab
Specified dose on specified days
Regorafinib
Specified dose on specified days
Leucovorin
Specified dose on specified days
Fluorouracil
Specified dose on specified days
Oxaliplatin
Specified dose on specified days
Enzalutamide
Specified dose on specified days
Sunitinib
Specified dose on specified days
Pemetrexed
Specified dose on specified days
Pembrolizumab
Specified dose on specified days

Locations

Country Name City State
Argentina Centro Oncologico y de Investigacion Buenos Aires Berazategui Buenos Aires
Argentina Local Institution - 0201 Buenos Aires
Argentina Local Institution Caba
Argentina Local Institution - 0030 Caba Buenos Aires
Argentina Local Institution - 0170 Cordoba
Argentina Local Institution - 0349 Cordoba
Argentina Local Institution - 0191 San Miguel De Tucumán Tucuman
Australia Local Institution Adelaide South Australia
Australia North Coast Area Health Service NCAHS - The North Coast Cancer Institute NCCI - Coffs Harbour Health Campus Coffs Harbour New South Wales
Australia Local Institution - 0196 Elizabeth Vale South Australia
Australia Local Institution - 0365 Fitzroy Victoria
Australia Local Institution Greenslopes Queensland
Australia Cabrini Hospital Malvern Malvern Victoria
Australia Local Institution - 0062 North Sydney New South Wales
Australia Local Institution South Brisbane Queensland
Australia Local Institution - 0347 Southport Queensland
Australia Local Institution - 0009 Sydney New South Wales
Australia Calvary Mater Newcastle Waratah New South Wales
Australia Westmead Hospital Westmead New South Wales
Austria LKH-Univ. Klinikum Graz Graz Steiermark
Austria Ordensklinikum Linz GmbH Elisabethinen Linz Upper Austria
Austria Allgemeine Krankenhaus Wien Vienna
Austria Local Institution - 0145 Wels
Austria Allgemeines Krankenhaus Wien Wien
Belgium Local Institution - 0329 Brussel
Belgium Universitair Ziekenhuis Gent Gent
Belgium UZ Brussel Campus Jette Jette
Belgium Local Institution - 0261 Liege
Belgium Local Institution - 0293 Sint-Niklaas
Belgium Local Institution - 0157 Yvoir
Brazil Local Institution - 0264 Barretos Sao Paulo
Brazil Local Institution - 0260 Belo Horizonte Minas Gerais
Brazil Local Institution - 0155 Ijui RIO Grande DO SUL
Brazil Local Institution - 0093 Porto Alegre SAO Paulo
Brazil Local Institution - 0113 Porto Alegre Rio Grande Do Sul
Brazil Local Institution - 0331 Porto Alegre Rio Grande Do Sul
Brazil Local Institution - 0258 Rio de Janeiro
Brazil National Cancer Institute (INCA) Rio De Janeiro
Brazil Local Institution - 0262 Sao Jose do Rio Preto Sao Paulo
Brazil Local Institution - 0302 Sao Paulo
Brazil Local Institution - 0340 Sao Paulo
Brazil Local Institution - 0355 Sao Paulo SP
Brazil Local Institution - 0263 São Paulo SAO Paulo
Canada Local Institution - 0111 Edmonton Alberta
Canada Local Institution Halifax Nova Scotia
Canada Local Institution - 0040 Montreal Quebec
Canada Local Institution - 0308 Montreal Quebec
Canada Local Institution - 0168 Oshawa Ontario
Canada Local Institution - 0280 Toronto Ontario
Canada Local Institution Vancouver British Columbia
Chile Fundacion Arturo Lopez Perez Santiago Metropolitana
Chile Local Institution Santiago Metropolitana
Chile Local Institution - 0101 Santiago Metropolitana
Chile Local Institution - 0363 Temuco Araucania
Chile Local Institution - 0079 Vina Del Mar
China Local Institution - 0198 Beijing Beijing
China Jilin Cancer Hospital Changchun Jilin
China Local Institution - 0307 Changchun Jilin
China Hunan Cancer Hospital Changsha Hunan
China Local Institution - 0172 Changsha Hunan
China Xiangya Hospital Central South University Changsha Hunan
China Local Institution Guangzhou Guangdong
China Local Institution - 0304 Hangzhou Zhejiang
China Local Institution - 0306 Hangzhou
China Harbin Medical University - Cancer Hospital Harbin Heilongjiang
China Local Institution - 0245 Harbin Heilongjiang
China Local Institution - 0160 Harbin Shi Heilongjiang
China Local Institution - 0169 Hefei Anhui
China Local Institution - 0348 Nanjing Jiangsu
China Local Institution - 0188 Shanghai Shanghai
China Local Institution - 0223 Shanghai Shanghai
China Local Institution - 0278 Shanghai Shanghai
China Local Institution - 0305 Shanghai Shanghai
China Local Institution - 0325 Shanghai Shanghai
China Tangdu Hospital of Fourth Military Medical University Xian Shaanxi
Czechia FNHK Klinika onkologie a radioterapie Hradec Kralove
Czechia Local Institution - 0150 Olomouc
Czechia Univerzita Karlova v Praze a Vseobecna fakultni nemocnice v Praze Prague NY
Denmark Local Institution Odense C
Finland Local Institution Helsinki
France Local Institution - 0006 Bordeaux
France Local Institution - 0345 Clermont-Ferrand
France Centre Hospitalier Intercommunal de Creteil CHIC Creteil
France Centre Georges-Francois Leclerc Dijon Cedex
France CHU Dijon Dijon Cedex
France CHU Grenobles Alpes La Tronche
France Pole Biologie Pathologie Genetique - CHU de Lille Lille Cedex
France APHM - Hopital de la Timone Marseille
France Local Institution - 0153 Marseille Cedex 20
France Local Institution Montpellier
France Local Institution - 0182 Montpellier
France Local Institution - 0300 Nantes
France Local Institution - 0341 Nantes
France Hospital Saint-Louis Paris
France Local Institution - 0301 Paris
France Hopital europeen Georges Pompidou HEGP Paris Cedex 15
France Centre Hospitalier Lyon Sud Pierre-Benite Cedex
France Local Institution Rennes
France Hopital Musse Toulon
France Local Institution Toulouse Cedex
France Local Institution - 0362 Vandoeuvre-Les-Nancy Meurthe-Et-Moselle
France Local Institution - 0029 Villejuif
Germany Local Institution - 0163 Aachen
Germany Charite Universitaetsmedizin Berlin Berlin
Germany Elbe Klinikum Buxtehude Buxtehude Niedersachsen
Germany Local Institution - 0296 Cologne
Germany Universitaetsklinikum Essen Essen Nordrhein-Westfalen
Germany University of Freiburg Freiburg
Germany Local Institution Gera
Germany SRH Wald-Klinikum Gera GmbH Gera
Germany Local Institution Goettingen
Germany Universitatsmedizin Gottingen Gottingen
Germany UKE Neurochirurgische Klinik Hamburg
Germany Local Institution Heidelberg
Germany Local Institution - 0342 Heidelberg
Germany Thoraxklinik Heidelberg
Germany Local Institution - 0285 Heilbronn
Germany Local Institution - 0216 Jena
Germany Klinikum Kassel - Klinik fuer Haematologie, Onkologie und Immunologie Kassel Hessen
Germany Local Institution Kiel
Germany Unv Schleswig-Holstein Campus Kiel Kiel
Germany Local Institution Koeln
Germany Local Institution - 0298 Loewenstein
Germany Local Institution Mainz
Germany Marienhaus Klinikum Mainz Mainz
Germany LMU Muenchen Muenchen Bayern
Germany Local Institution - 0332 Nuremberg Bayern
Germany Universitaetsklinikum Tuebingen Tubingen
Germany Local Institution - 0277 Tuebingen
Greece General Hospital of Athens Laiko Athens
Greece Local Institution - 0126 Athens
Greece Local Institution - 0171 Athens
Greece Local Institution - 0295 Athens
Greece Local Institution - 0244 Heraklion Crete
Greece Local Institution Patras
Greece Local Institution - 0042 Piraeus
Greece Local Institution - 0215 Thessaloniki
Hong Kong Local Institution - 0339 Hong Kong
Hungary Local Institution - 0226 Budapest
Hungary Orszagos Koranyi TBC es Pulmonologiai Intezet Budapest
Hungary Local Institution - 0187 Debrecen
Hungary Local Institution - 0290 Gyongyossolymos Heves
Ireland Local Institution - 0227 Dublin
Ireland Local Institution Limerick
Israel Rambam Health Care Campus Haifa
Israel Local Institution - 0270 Jerusalem
Israel Local Institution Petach Tikva
Israel Sheba Medical Center Ramat Gan
Israel Local Institution - 0350 Tiqwa
Italy Local Institution - 0034 Bari
Italy Local Institution - 0002 Bergamo
Italy Local Institution - 0326 Candiolo
Italy Local Institution - 0359 Catania
Italy Local Institution Genova
Italy Local Institution - 0251 Genova
Italy Local Institution Meldola
Italy Local Institution - 0303 Meldola
Italy Local Institution - 0361 Meldola Fc
Italy Fondazione IRCCS istituto Neurologico Carlo Besta, Milan
Italy Local Institution - 0096 Milan
Italy Local Institution - 0351 Milan
Italy IRCCS Istituto Europeo di Oncologia Milano
Italy Local Institution Milano
Italy Local Institution Milano
Italy Local Institution - 0267 Milano
Italy Local Institution - 0327 Modena
Italy Local Institution - 0073 Napoli
Italy Local Institution - 0218 Napoli
Italy Local Institution - 0292 Napoli
Italy Istituto Oncologico Veneto Padova
Italy Local Institution - 0180 Ravenna
Italy Local Institution - 0033 Roma RM
Italy Local Institution - 0333 Rozzano MI
Italy Local Institution - 0003 Siena
Italy Local Institution - 0291 Terni
Italy Azienda Ospedaliera Citta della Salute e della Scienza Torino
Japan Local Institution - 0235 Chuo-ku Tokyo
Japan Local Institution - 0230 Chuo-ku Niigata-shi Niigata
Japan Local Institution - 0224 Fukuoka
Japan Local Institution - 0242 Hirosaki Aomori
Japan Local Institution - 0319 Hiroshima
Japan Local Institution - 0219 Kanazawa-shi Ishikawa
Japan Local Institution - 0356 Kashiwa-Shi Chiba
Japan Kobe City Medical Center General Hospital Kobe shi Hyogo
Japan The Cancer Institute Hospital of JFCR Koto-Ku Tokyo
Japan Aichi Cancer Center Hospital Nagoya Aichi
Japan Miyagi Cancer Center Natori-shi Miyagi
Japan Local Institution - 0236 Niigata-Shi Niigata
Japan Kindai University Hospital Osakasayama Osaka
Japan Keio University Hospital Shinjuku Tokyo
Japan Local Institution - 0212 Takatsuki shi Osaka
Japan University of Tsukuba Hospital Tsukuba Ibaraki
Korea, Republic of National Cancer Center Gyeonggi-do
Korea, Republic of Local Institution - 0221 Seongnam-si
Korea, Republic of Asan Medical Center Seoul Songpa-gu
Korea, Republic of Local Institution - 0206 Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Local Institution - 0207 Suwon Si
Mexico Local Institution - 0337 Ciudad de Mexico
Mexico Local Institution - 0344 Ciudad de Mexico
Mexico Local Institution - 0346 Ciudad de Mexico
Mexico Local Institution - 0152 Leon Guanajuato
Mexico Local Institution - 0286 Monterrey Nuevo Leon
Mexico Local Institution - 0354 Monterrey Nuevo Leon
Mexico Local Institution - 0007 Morelia Michoacan
Mexico Local Institution - 0343 Santiago de Queretaro Queretaro
Mexico Local Institution - 0181 Tlalpan Ciudad De Mexico
Mexico Local Institution - 0338 Zapopan Jalisco
Netherlands Local Institution - 0335 Amsterdam Noord-Holland
Netherlands Local Institution Rotterdam
New Zealand Local Institution - 0271 Christchurch
New Zealand Southern District Hospital (SDHB) - Dunedin Hospital Dunedin
New Zealand Local Institution - 0269 Tauranga
Norway Local Institution - 0213 Bergen
Norway Oslo University Hospital Oslo
Peru Local Institution - 0179 Santiago de Surco Lima
Poland Local Institution - 0336 Biala Podlaska Lubelskie
Poland Local Institution - 0358 Bydgoszcz Kujawsko-pomorskie
Poland Local Institution - 0120 Gdansk
Poland Wojewodzkie Centrum Onkologii Gdansk
Poland Narodowy Instytut Onkologii Oddzial w Krakowie Krakow
Poland Local Institution - 0031 Lodz
Poland Local Institution - 0118 Lublin
Poland Local Institution - 0178 Poznan
Poland Local Institution Warsaw
Poland Local Institution - 0132 Warsaw
Poland Local Institution - 0151 Warszawa
Poland Local Institution - 0328 Warszawa
Portugal Local Institution - 0184 Lisboa
Portugal Local Institution - 0177 Lisbon
Portugal Local Institution - 0142 Porto
Puerto Rico Local Institution - 0334 San Juan
Romania Local Institution - 0129 Bucharest
Romania Local Institution - 0310 Bucharest
Romania Institutul Oncologic Prof. Dr. I. Chiricuta Cluj Napoca
Romania Local Institution - 0127 Cluj Napoca
Romania Local Institution - 0189 Cluj-Napoca
Romania Local Institution - 0265 Craiova
Romania Local Institution - 0133 Oradea
Russian Federation Local Institution - 0257 Krasnodar Krasnodar Region
Russian Federation Local Institution - 0256 Krasnoyarsk
Russian Federation N.N. Blokhin National Medical Research Center of Oncology Moscow
Russian Federation VitaMed LLC Moscow
Spain Hospital Teresa Herrera C.H.U.A.C. A Coruna
Spain Local Institution - 0173 Alicante
Spain Catalan Institute of Badalona Hospital Germans Trias i Pujol ICO Badalona
Spain Hospital Clinic de Barcelona Barcelona
Spain Hospital Universitari Vall d Hebron Barcelona
Spain Institut Catala dOncologia LHospitalet Barcelona
Spain Local Institution Barcelona
Spain Local Institution - 0323 Barcelona
Spain Local Institution - 0146 Burgos
Spain Local Institution Granada
Spain Hospital Ramon y Cajal Madrid
Spain Hospital Universitario 12 de Octubre Madrid
Spain Local Institution Madrid
Spain Local Institution Madrid
Spain Local Institution - 0008 Madrid
Spain Local Institution - 0097 Madrid
Spain Local Institution - 0112 Madrid
Spain Local Institution - 0273 Madrid
Spain Local Institution - 0357 Madrid
Spain Local Institution - 0360 Madrid
Spain Hospital Universitario Puerta de Hierro de Majadahonda Majadahonda Madrid
Spain Hospital Regional Universitario Carlos Haya Malaga
Spain Local Institution - 0353 Pamplona Navarra
Spain Onkologikoa Of San Sebastian San Sebastian Guipuzcoa
Spain Local Institution Santa Cruz de Tenerife
Spain Local Institution - 0352 Santander
Spain Hospital Universitario Virgen del Roco Sevilla
Spain Hospital Universitario Virgen Macarena Sevilla
Spain Hospital Universitario y Politecnico de La Fe Valencia
Spain Local Institution - 0020 Valencia
Sweden Local Institution Goteborg
Sweden Local Institution - 0036 Malmoe
Sweden Local Institution Umea
Switzerland Universitaetsspital Basel - Klinik fuer Onkologie Basel
Switzerland Local Institution - 0083 Zurich
Taiwan Local Institution - 0197 Tainan
Taiwan Local Institution - 0366 Tapei
Turkey Local Institution - 0330 Ankara
United Kingdom Local Institution - 0299 Edinburgh Scotland
United Kingdom Local Institution - 0086 London Greater London
United Kingdom Local Institution - 0141 London Greater London
United Kingdom Local Institution - 0272 London Greater London
United Kingdom University College Hospital London Greater London
United Kingdom Local Institution - 0231 Maidstone Kent
United Kingdom The Christie Hospital Manchester Greater Manchester
United Kingdom Local Institution - 0161 Northwood Middlesex
United Kingdom Local Institution - 0195 Southampton Hampshire
United States Local Institution Albuquerque New Mexico
United States Lehigh Valley Hospital Allentown Pennsylvania
United States University of Michigan Rogel Comprehensive Cancer Center UMCCC Ann Arbor Michigan
United States University of Colorado Aurora Colorado
United States Johns Hopkins Baltimore Maryland
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Dana_Farber Cancer Institute (DFCI) Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States Roswell Park Cancer Institute Buffalo New York
United States Charleston Oncology Charleston South Carolina
United States Levine Cancer Center Charlotte North Carolina
United States Local Institution Charlottesville Virginia
United States Local Institution Chattanooga Tennessee
United States Local Institution - 0105 Chicago Illinois
United States Oncology Hematology Care Cincinnati Ohio
United States Local Institution Cleveland Ohio
United States The Ohio University Columbus Ohio
United States Local Institution Dallas Texas
United States Duke University Durham North Carolina
United States St. Lukes University Health Network Easton Pennsylvania
United States Local Institution Greenville South Carolina
United States Local Institution - 0364 Houston Texas
United States Dartmouth-Hitchcock Medical Center Lebanon New Hampshire
United States University of Louisville-James Graham Brown Cancer Center Louisville Kentucky
United States Innovative Clinical Research Institute Lynwood California
United States Local Institution Madison Wisconsin
United States UW Health - UW Carbone Cancer Center - Medical Oncology Clinic Madison Wisconsin
United States Local Institution Maywood Illinois
United States Allina Health Minneapolis Minnesota
United States Tennesse Oncology Nashville Tennessee
United States Vanderbilt University Medical Center Nashville Tennessee
United States Allegheny Valley Hospital Natrona Heights Pennsylvania
United States Local Institution New Haven Connecticut
United States Local Institution New York New York
United States Local Institution New York New York
United States Weill Cornell Medical College New York New York
United States Weill Cornell Medical College New York New York
United States Florida Cancer Affiliates Ocala Florida
United States Local Institution - 0205 Omaha Nebraska
United States Local Institution Orlando Florida
United States Advocate Medical Group - Park Ridge - Luther Ln - Oncology Park Ridge Illinois
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Local Institution Philadelphia Pennsylvania
United States Local Institution - 0110 Pittsburgh Pennsylvania
United States Public Hospital of King County District 1 Valley Medical Center Renton Washington
United States Local Institution Saint Louis Missouri
United States Huntsman Cancer Institute Salt Lake City Utah
United States Local Institution San Francisco California
United States UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Melanoma Center San Francisco California
United States H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. Tampa Florida
United States University of Arizona College of Medicine Tucson Arizona
United States Georgetown-Lombardi Comprehensive Cancer Center Washington District of Columbia
United States University of Kansas Cancer Center Westwood Kansas
United States Cancer Center of Kansas Wichita Kansas

Sponsors (5)

Lead Sponsor Collaborator
Bristol-Myers Squibb Clovis Oncology, Inc., Exelixis, Janssen Pharmaceuticals, Novartis

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belgium,  Brazil,  Canada,  Chile,  China,  Czechia,  Denmark,  Finland,  France,  Germany,  Greece,  Hong Kong,  Hungary,  Ireland,  Israel,  Italy,  Japan,  Korea, Republic of,  Mexico,  Netherlands,  New Zealand,  Norway,  Peru,  Poland,  Portugal,  Puerto Rico,  Romania,  Russian Federation,  Spain,  Sweden,  Switzerland,  Taiwan,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events (AEs) From Day 1 up to 135 Days after discontinuation of treatment
Primary Incidence of drug related AEs From Day 1 up to 135 Days after discontinuation of treatment
Primary Incidence of AEs leading to Discontinuation From Day 1 up to 135 Days after discontinuation of treatment
Primary Incidence of Serious Adverse Events (SAEs) From signature of Informed Consent up to 135 Days after discontinuation of treatment
Primary Incidence of Select AEs From Day 1 up to 135 Days after discontinuation of treatment
Primary Incidence of Immune-Mediated AEs From Day 1 up to 135 Days after discontinuation of treatment
Primary Incidence of Death From signature of Informed Consent up to 135 Days after discontinuation of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases